Company / Return on Assets (ROA)
Celldex Therapeutics, Inc. Return on Assets (ROA) History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-44.4%
FY2025
5-year range
-44.4% / -19.9%
FY2023-FY2025
Trend
-122.8%
vs FY2024
Sector context
#153 of 158
Health Care
What the data says
Among 158 Health Care companies, Celldex Therapeutics, Inc. is in the bottom 3% for return on assets (roa). Declined from -30.4% to -44.4% over the past 2 years.
Based on SEC 10-K filings.
-44.4% in FY2025.
Declined from -30.4% to -44.4% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 158This company -44.4% Sector average -2.3%
▼
-1834.2% below sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) decreased 122.8% year-over-year.
- Currently 42.1pp below the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -44.4% | -122.8% |
| FY2024 | -19.9% | +34.4% |
| FY2023 | -30.4% | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026